AR051071A1 - Antagonismo de la actividad del receptor de interleuquina-21 - Google Patents

Antagonismo de la actividad del receptor de interleuquina-21

Info

Publication number
AR051071A1
AR051071A1 ARP050103287A ARP050103287A AR051071A1 AR 051071 A1 AR051071 A1 AR 051071A1 AR P050103287 A ARP050103287 A AR P050103287A AR P050103287 A ARP050103287 A AR P050103287A AR 051071 A1 AR051071 A1 AR 051071A1
Authority
AR
Argentina
Prior art keywords
activity
antagonists
receptor
fusion protein
interleuquina
Prior art date
Application number
ARP050103287A
Other languages
English (en)
Inventor
Deborah A Young
Mary Collins
Dunussi-Joannopoulos
Marion T Kasaian
Hara Richard Michael O
Matthew Whitters
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR051071A1 publication Critical patent/AR051071A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0368—Animal model for inflammation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Dermatology (AREA)

Abstract

Se describen métodos y composiciones para inhibir la actividad de la interleuquina-21 (IL-21)/el receptor de IL-21 (MU-1) usando antagonistas de IL-21 o del receptor IL-21 (ôIL-21Rö o ôMU-1ö). Los antagonistas de IL-21/IL-21R pueden usarse para inducir la supresion inmune in vivo, por ejemplo, para tratar, mejorar o prevenir los trastornos autoinmunes o inflamatorios, incluyendo, por ejemplo, la enfermedad intestinal inflamatoria (IBD), l artritis reumatoide (RA), el rechazo de transplantes/injertos, la psoriasis, el asma, la fibrosis y el lupus eritematoso sistémico (SLE). Reivindicacion 1: Una proteína de fusion caracterizado porque está compuesta por un dominio extracelular de un IL-21R y un fragmento de inmunoglobulina Fc, donde el IL-21R tiene una secuencia de aminoácidos al menos 90% idéntica a la secuencia detallada en SEQ ID N. 2, y donde la proteína de fusion es capaz de unirse a IL-21.
ARP050103287A 2004-08-05 2005-08-05 Antagonismo de la actividad del receptor de interleuquina-21 AR051071A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59908604P 2004-08-05 2004-08-05
US63917604P 2004-12-23 2004-12-23

Publications (1)

Publication Number Publication Date
AR051071A1 true AR051071A1 (es) 2006-12-20

Family

ID=37309615

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103287A AR051071A1 (es) 2004-08-05 2005-08-05 Antagonismo de la actividad del receptor de interleuquina-21

Country Status (16)

Country Link
US (2) US20060039902A1 (es)
EP (1) EP1773394A2 (es)
JP (1) JP2008508885A (es)
KR (1) KR20070057789A (es)
AR (1) AR051071A1 (es)
AU (1) AU2005332996A1 (es)
BR (1) BRPI0514138A (es)
CA (1) CA2574848A1 (es)
CR (1) CR8891A (es)
EC (1) ECSP077226A (es)
IL (1) IL181044A0 (es)
MX (1) MX2007001509A (es)
NO (1) NO20070973L (es)
RU (1) RU2007102287A (es)
TW (1) TW200608995A (es)
WO (1) WO2006135385A2 (es)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
US20110075507A1 (en) * 1997-10-24 2011-03-31 Revalesio Corporation Diffuser/emulsifier
US7654728B2 (en) * 1997-10-24 2010-02-02 Revalesio Corporation System and method for therapeutic application of dissolved oxygen
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
ZA200500480B (en) * 2002-07-15 2006-10-25 Wyeth Corp Methods and compositions for modulating T helper (TH) cell development and function
US7495085B2 (en) * 2003-03-14 2009-02-24 Wyeth Antibodies against human or mouse IL-21 receptor
CA2518854A1 (en) * 2003-03-21 2004-10-07 Wyeth Treating immunological disorder using agonists of interleukin-21/interleukin-21 receptor
AR052289A1 (es) * 2005-02-14 2007-03-07 Wyeth Corp Anticuerpos para interleucina-17f y otros antagonistas de la senalizacion de il-17f y sus usos
BRPI0608210A2 (pt) 2005-02-14 2010-11-09 Wyeth Corp métodos de diagnóstico de um distúrbio relacionado com il-17f em um indivìduo e de seleção de compostos capazes de inibirem a ligação de il-17f em il-17r, uso de um antagonista de il-17f, composição farmacêutica, e, adjuvante de vacina
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
MX2007012887A (es) 2005-04-18 2007-12-10 Novo Nordisk As Variantes il-21.
BRPI0617378B8 (pt) * 2005-10-14 2022-09-20 Chugai Pharmaceutical Co Ltd Uso de um inibidor de il-6 para produzir uma composição farmacêutica para suprimir dano a um ilhota transplantada depois do transplante de ilhota; e aperfeiçoar a viabilidade de uma ilhota em um transplante de ilhota
RU2450830C2 (ru) * 2005-10-21 2012-05-20 Чугаи Сейяку Кабусики Кайся Средства для лечения кардиопатии
AR057582A1 (es) * 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
TW200803894A (en) * 2005-11-25 2008-01-16 Univ Keio Prostate cancer therapeutic agents
CA2632218A1 (en) * 2005-11-28 2007-10-11 Zymogenetics, Inc. Il-21 receptor antagonists
US20070122413A1 (en) * 2005-11-28 2007-05-31 Sivakumar Pallavur V Il-21 antagonists
WO2007086490A1 (ja) * 2006-01-27 2007-08-02 Keio University 脈絡膜血管新生を伴う疾患の治療剤
JP5754875B2 (ja) * 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
US8784897B2 (en) 2006-10-25 2014-07-22 Revalesio Corporation Methods of therapeutic treatment of eyes
AU2007308840C1 (en) 2006-10-25 2014-09-25 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
US8609148B2 (en) * 2006-10-25 2013-12-17 Revalesio Corporation Methods of therapeutic treatment of eyes
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
US8784898B2 (en) 2006-10-25 2014-07-22 Revalesio Corporation Methods of wound care and treatment
WO2008052143A2 (en) 2006-10-25 2008-05-02 Revalesio Corporation Mixing device and output fluids of same
AU2007349224B2 (en) * 2006-10-25 2014-04-03 Revalesio Corporation Methods of wound care and treatment
AU2007310777A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S IL-21 variants
CA2671665A1 (en) * 2006-12-21 2008-06-26 Novo-Nordisk A/S Interleukin-21 variants with altered binding to the il-21 receptor
CA2675625C (en) * 2007-01-23 2016-09-13 Shinshu University Chronic rejection inhibitor
CL2008000883A1 (es) * 2007-03-28 2008-10-03 Wyeth6 3 Metodo de deteccion de compuestos capaces de antagonizar la senalizacion de il-17f/il-17a; compuesto identificado por dicho metodo; uso de una cantidad de un antagonista de senalizacion de il-17f/il-17a, composicion farmaceutica que comprende dicho a
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
WO2010062628A1 (en) * 2008-10-27 2010-06-03 Revalesio Corporation Compositions and methods for treating asthma and other lung disorders
US20100303871A1 (en) * 2007-10-25 2010-12-02 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US9745567B2 (en) * 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US20100303917A1 (en) * 2007-10-25 2010-12-02 Revalesio Corporation Compositions and methods for treating cystic fibrosis
US20100029764A1 (en) * 2007-10-25 2010-02-04 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US20100009008A1 (en) * 2007-10-25 2010-01-14 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
US10125359B2 (en) * 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US20100015235A1 (en) * 2008-04-28 2010-01-21 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US20090227018A1 (en) * 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
JP5586470B2 (ja) * 2007-10-25 2014-09-10 リバルシオ コーポレイション 静菌性または殺菌性組成物および方法
US20090263495A1 (en) * 2007-10-25 2009-10-22 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
US20100303918A1 (en) * 2007-10-25 2010-12-02 Revalesio Corporation Compositions and methods for treating asthma and other lung disorders
CN103772502B (zh) 2007-12-07 2017-03-29 津莫吉尼蒂克斯公司 抗人il‑21单克隆抗体
EP2257634A1 (en) * 2008-03-12 2010-12-08 Wyeth LLC Method for identifying cells suitable for large-scale production of recombinant proteins
WO2009132821A1 (en) * 2008-04-28 2009-11-05 Giuliani International Limited Interleukin (il-21) binding proteins and methods of making and using same
CA2723215A1 (en) * 2008-05-01 2009-11-05 Revalesio Corporation Compositions and methods for treating digestive disorders
AR071885A1 (es) 2008-05-23 2010-07-21 Wyeth Corp Proteinas de union al receptor de interleuquina 21
JP2011520989A (ja) 2008-05-23 2011-07-21 ワイス・エルエルシー インターロイキン−２１受容体の結合性タンパク質を利用する治療法
CA2728243C (en) * 2008-06-05 2020-03-10 National Cancer Center Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer
US20100075329A1 (en) * 2008-09-23 2010-03-25 O'toole Margot Methods for predicting production of activating signals by cross-linked binding proteins
BRPI0920546B1 (pt) 2008-10-08 2021-08-10 Cambridge Enterprise Limited Métodos para identificar e selecionar um paciente com esclerose múltipla
US20100098659A1 (en) * 2008-10-22 2010-04-22 Revalesio Corporation Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
WO2011022394A2 (en) * 2009-08-17 2011-02-24 A&G Pharmaceutical, Inc. Materials and methods for the development of an antigen-specific immune non-responsiveness state
KR101004363B1 (ko) * 2010-03-19 2010-12-28 가톨릭대학교 산학협력단 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＩＬ－２１ 이중 길항제
US9464329B2 (en) 2010-03-26 2016-10-11 Monsanto Technology Llc Portable systems and methods for amplifying nucleotides and detecting nucleotide sequences
US9198929B2 (en) 2010-05-07 2015-12-01 Revalesio Corporation Compositions and methods for enhancing physiological performance and recovery time
ES2932398T3 (es) 2010-05-28 2023-01-18 Chugai Pharmaceutical Co Ltd Potenciador de la respuesta de las células T antitumorales
WO2012012531A2 (en) * 2010-07-20 2012-01-26 Beth Israel Deaconess Medical Center, Inc. Compositions and methods featuring il-6 and il-21 antagonists
EA201300228A1 (ru) 2010-08-12 2013-06-28 Ревалезио Корпорейшн Композиции и способы лечения таупатии
CN109021069A (zh) 2011-01-18 2018-12-18 比奥尼斯有限责任公司 调节γ-C-细胞因子活性的组合物及方法
KR20130011056A (ko) * 2011-07-20 2013-01-30 주식회사에이앤알쎄라퓨틱스 염증표적 수용체 및 염증 질환 치료용 약물 운반체
ES2685076T3 (es) * 2011-08-30 2018-10-05 Abb Schweiz Ag Transformador de tipo seco
WO2013096732A2 (en) * 2011-12-23 2013-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating or preventing viral diseases by blocking interleukin-21
US20160215042A1 (en) * 2013-04-19 2016-07-28 The Brigham And Women's Hospital, Inc. Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
EP3128997B1 (en) 2014-04-08 2020-08-05 Boston Pharmaceuticals Inc. Binding molecules specific for il-21 and uses thereof
CN107249633A (zh) * 2014-12-19 2017-10-13 迈博太科公司 用于抑制il‑21介导的人细胞活化的组合物、试剂盒和方法
ES2884357T3 (es) 2015-10-09 2021-12-10 Bioniz Llc Modulación de la actividad de las citocinas gamma-c
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
WO2018013585A1 (en) * 2016-07-12 2018-01-18 Flagship Pioneering, Inc. Methods and compositions for modulating thymic function
US10875828B2 (en) * 2016-08-05 2020-12-29 The Regents Of The University Of California Mithrene and methods of fabrication of mithrene
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
CN110124029B (zh) * 2019-04-19 2023-08-11 中山大学附属第六医院 Il-6r抗体及羊水干细胞在制备用于治疗nec的药物中的应用
WO2020227019A1 (en) 2019-05-03 2020-11-12 Bioniz, Llc Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US425871A (en) * 1890-04-15 Half to james l
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) * 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) * 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4737323A (en) * 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP3101690B2 (ja) * 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5399677A (en) * 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
SI9720020B (en) * 1996-02-09 2001-12-31 Basf Ag Human antibodies that bind human TNF alpha
US6350892B1 (en) * 1997-09-23 2002-02-26 Bristol-Myers Squibb Company Trifluoromethyl ketone analogs as selective cPLA2 inhibitors
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
DE60141234D1 (de) * 2000-04-05 2010-03-18 Zymogenetics Inc Löslicher Zytokinrezeptor zalpfa11
JP2005508915A (ja) * 2001-10-04 2005-04-07 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー インターロイキン２１受容体活性を調節する方法および組成物
WO2003087320A2 (en) * 2002-04-09 2003-10-23 Beth Israel Deaconess Medical Center, Inc. Antagonists of il-21 and modulation of il-21-mediated t cell responses
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
ZA200500480B (en) * 2002-07-15 2006-10-25 Wyeth Corp Methods and compositions for modulating T helper (TH) cell development and function
US7495085B2 (en) * 2003-03-14 2009-02-24 Wyeth Antibodies against human or mouse IL-21 receptor
CA2518854A1 (en) * 2003-03-21 2004-10-07 Wyeth Treating immunological disorder using agonists of interleukin-21/interleukin-21 receptor
US20060024268A1 (en) * 2004-05-19 2006-02-02 Wyeth Modulation of immunoglobulin production and atopic disorders
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis

Also Published As

Publication number Publication date
RU2007102287A (ru) 2008-09-10
CR8891A (es) 2007-08-28
WO2006135385A2 (en) 2006-12-21
CA2574848A1 (en) 2006-12-21
MX2007001509A (es) 2007-03-27
NO20070973L (no) 2007-05-04
AU2005332996A1 (en) 2006-12-21
IL181044A0 (en) 2007-07-04
WO2006135385A3 (en) 2007-02-22
US20060039902A1 (en) 2006-02-23
US20080241098A1 (en) 2008-10-02
EP1773394A2 (en) 2007-04-18
BRPI0514138A (pt) 2008-05-27
TW200608995A (en) 2006-03-16
JP2008508885A (ja) 2008-03-27
KR20070057789A (ko) 2007-06-07
ECSP077226A (es) 2007-03-29

Similar Documents

Publication Publication Date Title
AR051071A1 (es) Antagonismo de la actividad del receptor de interleuquina-21
MX2022011309A (es) Receptores de celulas t.
CR20200375A (es) Anticuerpos agonistas contra pd-1 y usos de estos
RU2013128896A (ru) Сконструированные белки повторов, которые связываются с сывороточным альбумином
MX2018012268A (es) Receptores de celulas t.
ATE514713T1 (de) Antikörper gegen pd-1 und ihre verwendung
PE20080556A1 (es) Composicion que comprende una poblacion aislada de moleculas ctla4-ig a partir de un medio de cultivo liquido y metodos para su obtencion
DK1765860T3 (da) Ny-ESO-T.cellereceptor med höj affinitet
RS54133B1 (en) ANTI-IL-6 ANTIBODIES, PREPARATIONS, PREPARATION AND USE PROCEDURES
AR072749A1 (es) Anticuerpos contra receptor del factor de la necrosis tumoral (baffr) y composiciones farmaceuticas
TW200740844A (en) Novel MAdCAM antibodies
AR065433A1 (es) Anticuerpos anti-cxcl13
DK1824970T3 (da) Thricoderma reesei-glycoamylase og homologer heraf
TW200800959A (en) Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
RU2021132734A (ru) Химерные рецепторы антигена, нацеленные на psca
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
DE60327471D1 (de) Verfahren und zusammensetzungen zur reinigung von nukleinsäure aus einer wirtszelle
WO2008130382A3 (en) Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
MX2012000133A (es) Quimera de adn polimerasa del fago phi29.
WO2007055823A3 (en) Gpcr expressing cell lines and antibodies
MX2021015160A (es) Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso.
MX2012001278A (es) Anticuerpos de dominio simple anti-receptor tgf-beta tipo ii.
PE20100141A1 (es) Proteina de union al receptor de interleuquina 21
WO2008060814A3 (en) ANTI-IL-13Rα1 ANTIBODIES AND THEIR USES THEREOF
ATE462728T1 (de) Antikörper zur identifizierung und/oder isolierung von wenigstens einer zellpopulation ausgewählt aus hämatopoetischen stammzellen, neuronalen stammzellen, progenitoren neuronalen zellen, mesenchym-stammzellen und mesenchym- progenitoren stammzellen

Legal Events

Date Code Title Description
FB Suspension of granting procedure